EMAIL DETAILS

Ok - what do you need to follow up with him?


Eric D. Schwerin
Rosemont Seneca Partners, LLC
1010 Wisconsin Ave., NW
Suite 705
Washington, DC 20007
(202) 333-1880
eschwerin@rosemontseneca.com
P Consider the environment before printing this email.

On Sep 22, 2014, at 1:18 PM, Hunter Biden <hbiden@rosemontseneca.com> wrote:

> Biz-dev. Mkts like KZ, Africa etc...
>
> RHB
> 202.333.1880
>
> On Sep 22, 2014, at 1:16 PM, Eric Schwerin <eschwerin@rosemontseneca.com> wrote:
>
>> What’s the follow up on this? I looked through the presentation you gave me - is it a business development play or a capital raise play? Seemed more biz dev?
>>
>>
>> Eric D. Schwerin
>> Rosemont Seneca Partners, LLC
>> 1010 Wisconsin Ave., NW
>> Suite 705
>> Washington, DC 20007
>> (202) 333-1880
>> eschwerin@rosemontseneca.com
>> P Consider the environment before printing this email.
>>
>> On Sep 12, 2014, at 10:35 AM, Hunter Biden <hbiden@rosemontseneca.com> wrote:
>>
>>> Pls put on list for follow up.
>>>
>>> RHB
>>> 202.333.1880
>>>
>>> Begin forwarded message:
>>>
>>>> From: Corrado Cusano <corrado.cusano@medtag.net>
>>>> Date: September 11, 2014 at 3:26:07 PM CDT
>>>> To: "rhb@rspdc.com" <rhb@rspdc.com>
>>>> Cc: Sabina Colombo <sabina.colombo@medtag.net>, "franco@georgetowneg.com" <franco@georgetowneg.com>
>>>> Subject: MedTAG
>>>>
>>>> Dear Hunter,
>>>> it was a pleasure to meet you today.
>>>> As agreed, please find attached the presentation, the company profile, the THF project overview and the clinical research project.
>>>> I'm available anytime to discuss with you and Franco how we can start our collaboration.
>>>> I really hope to start something successful together with you.
>>>> Look forward to hearing from you and coming back to Washington soon.
>>>>
>>>> Many thanks and best regards
>>>>
>>>> Corrado
>>>>
>>>>
>>>>
>>>> Corrado Cusano
>>>> President & CEO
>>>> _________________
>>>> MEDTAG Ltd
>>>> England
>>>> 12, Bridewell Place, 3rd Floor, East Unit
>>>> London EC4V 6AP
>>>>
>>>> www.medtag.net
>>>>
>>>> The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any review, retransmission, dissemination of this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.
>>> <3b_Corporate Presentation.pdf>
>>> <1_Corporate profile_2014.pdf>
>>> <2_THF Project Overview.pdf>
>>> <4_Proposition synthetique _ Centre National de Recherche en Infectiologie_Gabon.pdf>
>>